Indian multinational pharmaceutical company, Lupin, has expanded into the CDMO market.

The company has appointed Abdelaziz Toumi as the CEO of its newly established subsidiary, Lupin Manufacturing Solutions (LMS) which will focus on developing, manufacturing, and selling APIs while expanding into the CDMO market. Toumi brings over 20 years of experience in biotech, pharma, and CDMO sectors, having held leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, with his expertise expected to help LMS become a preferred global partner in the API and CDMO market.

Global pharma major Lupin Limited (Lupin) announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.

Abdel is a seasoned leader with a blend of scientific and commercial skills, and brings over two decades of rich experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. Abdel will be based in Switzerland and will spend considerable time in India.

Abdel holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.

Commenting on the appointment, Lupin’s Managing Director, Nilesh Gupta said, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”

For more, please find the original story source here.